ViaCyte maintains a broad intellectual property portfolio developed primarily through internal discovery.  Our patent portfolio reflects the research & development of our two core platform technologies: human pluripotent stem cells and devices to deliver cell products made from human pluripotent stem cells.

We have over 200 patent applications pending worldwide.  Our key stem cell patents in the United States include:

• U.S. Patent Nos. 7,510,876; 7,541,185; 7,695,963; and 7,704,738 which relate to definitive endoderm cells, methods for identifying factors for differentiating definitive endoderm (i.e., screening), expanding definitive endoderm, and making definitive endoderm
• U.S. Patent Nos. 7,534,608 and 7,695,965 which relate to treatment of diabetes using Pro-Islet™ cells (pancreatic progenitors)
• U.S. Patent Nos. 7,695,963 and 7,432,104 which relate to parts of the pancreatic progenitor manufacturing process